Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Prostatic Neoplasms 27Breast Neoplasms 23Neoplasm Metastasis 14Glioma 14Carcinoma, Non-Small-Cell Lung 14Lymphoma 12Lung Neoplasms 11Glioblastoma 11Neuroblastoma 10Lymphoma, Non-Hodgkin 9Carcinoma, Renal Cell 9Brain Neoplasms 9Medulloblastoma 8Ovarian Neoplasms 7Neoplasms 7Multiple Myeloma 7Ependymoma 7Carcinoma, Hepatocellular 7Wilms Tumor 6Thyroid Neoplasms 6Sarcoma 6Rectal Neoplasms 6Pancreatic Neoplasms 6Osteosarcoma 6Melanoma 6Fallopian Tube Neoplasms 6Central Nervous System Neoplasms 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5

Interventions

trebananib 1selurampanel 1saracatinib 1Sunitinib 1Postmortem Imaging 1Magnetic Resonance Spectroscopy 1High-Energy Shock Waves 1Cyproheptadine 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma, Endometrial Stromal × Magnetic Resonance Spectroscopy × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡